This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Dr Banerjee: an update on the results of the SOLO-1 study and its significance

Prescribing Information

Length: 03:31

Watch Dr Banerjee give a breakdown of the key data from the SOLO-1 study, discussing its significance and how it could change the treatment paradigm for women with newly diagnosed BRCA mutated advanced ovarian cancer.

More information about LYNPARZA™ (olaparib):

Supporting documentation

100 mg and 150 mg film coated tablets
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

50 mg hard capsules
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-17803 | Date of Preparation: August 2019